MaxBetto
< Back

Mai Hontama vs Alina Charaeva

Tennis
2025-09-11 13:59
Start: 2025-09-12 04:10

Summary

Pick: home
EV: 0.1424

Current Odds

Home 2.74|Away 1.46
Best Odds

Match Info

Match key: Mai Hontama_Alina Charaeva_2025-09-12

Analysis

Summary: Given nearly identical profiles and no clear edges in the provided research, the market’s heavy lean to Charaeva appears overstated; Hontama at 2.38 offers value based on our 48% win estimate, but uncertainty is high.

Highlights

  • Market-implied probability for Hontama: ~42.0%; our estimate: 48%
  • Positive EV at current price: ~14.2% ROI per unit staked under our model

Pros

  • + Price for Hontama (2.38) exceeds our minimum fair odds (2.083) given our probability estimate
  • + Profiles and recent results provided show no clear advantage for Charaeva to justify the market gap

Cons

  • - Research lacks head-to-head, ranking, injury and explicit surface/venue data—this increases uncertainty
  • - Both players’ recent form is poor, making performance outcomes more volatile

Details

We note the market prices Alina Charaeva as a clear favorite at 1.57 (implied ~63.7%) while Mai Hontama is offered at 2.38 (implied ~42.0%). The available research shows nearly identical career records and recent results for both players (each ~10-21 across clay and hard), with no clear form or surface edge in the provided data. Given those near-parallels, we view the match as much closer to even than the market implies. We therefore assign a true win probability to Hontama of 48%, which is notably higher than the market-implied 42.0% for the 2.38 price. At that estimate Hontama represents positive expected value versus the current moneyline. We also flag high uncertainty due to lack of H2H, ranking, injury or surface-specific advantage in the provided sources, so the value is speculative but present at the quoted price.

Key factors

  • Both players show nearly identical career records (10-21) in the provided profiles
  • Recent match listings for both are similarly poor and provide no clear form advantage
  • Market prices favor Charaeva heavily (1.57) despite lack of differentiating data, creating potential value on Hontama